Expand EYEN Menu
EYEN MENU

EYEN Latest Press Releases

-- November 15, 2024 --

Eyenovia Provides Update on Phase 3 CHAPERONE Study Globe Newswire 7:00 AM

-- November 12, 2024 --

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- November 7, 2024 --

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th Globe Newswire 7:00 AM

-- October 23, 2024 --

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet Globe Newswire 7:00 AM

-- October 1, 2024 --

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device Globe Newswire 7:00 AM

-- September 27, 2024 --

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering Globe Newswire 8:30 AM

-- September 26, 2024 --

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery Globe Newswire 7:00 AM

-- September 9, 2024 --

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization PRNewswire 3:00 AM

-- September 5, 2024 --

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. Globe Newswire 7:00 AM

-- September 3, 2024 --

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer Globe Newswire 7:00 AM

-- August 23, 2024 --

Eyenovia Announces Closing of Public Offering Globe Newswire 11:42 AM

-- August 21, 2024 --

Eyenovia Announces Pricing of $5.14 Million Public Offering Globe Newswire 9:29 AM

-- August 20, 2024 --

Eyenovia, Inc. Announces Proposed Public Offering Globe Newswire 5:09 PM

-- August 13, 2024 --

Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference Globe Newswire 7:00 AM

-- August 12, 2024 --

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- August 8, 2024 --

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th Globe Newswire 7:00 AM

-- August 7, 2024 --

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. Globe Newswire 5:11 PM
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States PRNewswire 8:00 AM

-- July 30, 2024 --

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease Globe Newswire 8:00 AM

-- July 23, 2024 --

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease Globe Newswire 7:00 AM

-- July 1, 2024 --

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities Business Wire 6:50 AM

-- June 28, 2024 --

Eyenovia Announces Pricing of $5M Registered Direct Offering Globe Newswire 8:00 AM